SACHSE Andreas,SACHSE Andreas,MARGOLIN David Harris,MARGOLIN David Harris
申请号：
SI200731746
公开号：
SI2066352T1
申请日:
2007.09.11
申请国别(地区):
SI
年份:
2016
代理人:
摘要：
A method for treatment of multiple sclerosis (MS) with Campath-1H with significant efficacy and a favourable safety profile is described, which offers an acceptable benefit/risk ratio. Especially described is the use of Campath-1H (alemtuzumab) for the production of a medicament for the treatment of multiple sclerosis (MS), comprising a first treatment cycle followed by at least one further treatment cycle of Campath-1H (alemtuzumab), in which each treatment cycle comprises 1-5 daily doses which are applied on consecutive days, wherein the daily dose is >0 and ‰¤ 12 mg, and wherein each treatment cycle is separated from the next cycle by at least 1 - 24 months. Also described are treatment regimens comprising the administration of less than 12 mg/day of Campath-1H for a period of 1-5 consecutive days.
